ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis

详细信息	查看全文 | 推荐本文 |

• 作者：Man Luo^a ; ^b ; ¹ ; Jiaoxing Li^a ; ¹ ; Xiaowei Xu^c ; ¹ ; Xunsha Sun^a ; Wenli Sheng^a ; ^{shengwl@mail.sysu.edu.cn}
• 关键词：Clopidogrel ; Adverse clinical events ; ABCB1 ; Polymorphism ; Meta-analysis
• 刊名：Thrombosis Research
• 出版年：2012
• 期刊代码：247_00493848
• 类别：med
• 出版时间：June, 2012
• 卷：129
• 期：6
• 页码：754-759
• 文件大小：727 K

摘要

Introduction

The ABCB1 C3435T polymorphism limits oral bioavailability of clopidogrel and may influence prognosis of patients treated with clopidogrel. Several studies have examined the association between the C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients, but the results were inconsistent. To assess the role of the C3435T polymorphism in the impact on clinical outcomes, a meta-analysis was conducted.

Methods

6 studies with 10,153 subjects were included in this meta-analysis. Fixed- or random-effects model was chosen according to heterogeneity. Publication bias was evaluated by fail-safe numbers.

Results

The association of the C3435T polymorphism with risk of overall recurrent ischemic events in clopidogrel treated patients was not statistically significant for all genetic models (OR = 1.13, 95%CI: 0.78-1.64, P = 0.51; OR = 1.15, 95%CI: 0.99-1.33, P = 0.07; OR = 1.19, 95%CI: 0.81-1.76, P = 0.37). Significant association was identified between the C3435T polymorphism and risk of short-term recurrent ischemic events (OR = 1.55, 95%CI: 1.09-2.20, P = 0.01; OR = 1.41, 95%CI: 1.06-1.87, P = 0.02; OR = 1.77, 95%CI: 1.19-2.63, P = 0.005). No statistically significant association between the C3435T polymorphism and stent thrombosis (OR = 0.79, 95%CI: 0.47-1.32, P = 0.37) or bleeding (OR = 0.98, 95%CI: 0.79-1.21, P = 0.82) was identified. The results may be affected by publication bias.

Conclusions

This meta-analysis failed to show an association between the ABCB1 C3435T polymorphism and risk of overall recurrent ischemic events, stent thrombosis or bleeding in clopidogrel treated patients. However, the association between TT homozygotes of the C3435T polymorphism and risk of short-term recurrent ischemic events may exist, but needs more studies to confirm.